Abstract:e16191 Background: The rising elderly population worldwide has led to an increase in cases of liver cancer among individuals aged ≥65 years. With the advancement of medical treatments, the management of unresectable hepatocellular carcinoma (uHCC) now predominantly involves immunotherapy combination therapy. However, existing data in elderly patients are limited. Therefore, we conducted a retrospective analysis on the efficacy and safety of immune combination therapy compared with TKI monotherapy in elderly uHCC patients. Methods: A retrospective analysis was conducted on uHCC patients aged ≥65 years at the First Hospital of Jilin University between March 2019 and July 2023. The targeted therapy used in this study included, but not limited to, sorafenib, lenvatinib. PD-1/PD-L1 inhibitors such as pembrolizumab and atezolizumab were also utilized. Follow-up was conducted until death, loss to follow-up, or December 2023. The primary endpoint was overall survival (OS), while the secondary endpoints were progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), adverse events (AEs) and immune-related AEs (irAEs). Results: A total of 70 patients were included in this study, with 33 patients receiving monotherapy, and 37 patients receiving immune combination therapy. The median age was 68 years old, with 78.8% being male. The combination therapy group had a higher ORR (10.8% vs. 3.0%) DCR (48.5% vs. 45.9%) compared to the monotherapy group. However, there were no statistically significant differences in median PFS (7.0 vs. 12.0 months) and median OS (9.8 vs. 17.5 months) between the two groups. Among the subgroups, combination therapy showed better results except for patients with ascites. Immune combination therapy appeared to be superior to monotherapy in terms of both PFS (6.2 vs. 6.8 months, P = 0.888) and OS (6.8 vs. 10.2 months, P = 0.888). Multivariate analysis showed that elevated total bilirubin may be a risk factor for OS in patients ≥65 years old. Regarding safety, the adverse event (AE) rate was 39.3% in the monotherapy group. The most common AEs reported were abdominal distension (18.2%), fatigue (15.2%), and proteinuria (6.1%). In the combination therapy group, the AE rate was higher at 59.4%, with the most common AEs being thyroid function abnormalities (24.3%), fatigue(24.3%), decreased appetite(18.9%), and hypertension(18.9%). The rate of drug withdrawal due to adverse reactions was significantly higher in patients receiving combination therapy compared to those receiving monotherapy (40.5% vs. 12.1%, P = 0.008). Conclusions: In elderly uHCC patients (≥65 years old), immune combination therapy shows a higher ORR and potentially longer PFS and OS except patients with ascites. AEs and drug withdrawal rates are higher in the combination therapy group. Further discussions are needed to determine the optimal treatment strategy for elderly uHCC patients.

Nonsurgical combination therapy for primary liver cancer in the elderly: analysis of 52 patients

Evaluation of the Efficacy for Alternated Treatment on Primary Liver Cancer by Interventional Therapy in Combination with Fractionated Stereotactic Conformal Radiotherapy

Prolong Overall Survival Rate for Patients with Liver Cancer Receiving Double Interventional Therapy

Clinical Analysis of the Effect of Contrast-enhanced Ultrasonography on Trans-arterial Chemoembolization for Advanced Liver Cancer in the Elderly

Comparison of Treatment Safety and Patient Survival in Elderly Versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: a Propensity Score Matching Study.

Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is As Effective in Elderly Patients As It is in Younger Patients: A Propensity Score Matching Analysis

[Multi-Modal Serial Therapy for Primary Liver Cancer in Senile Patients: a Report of 153 Cases].

Effect of interventional chemotherapy on cellular immune function and prognosis in elderly patients with primary hepato-cellular carcinoma

Do Elderly Patients With Stage I-II Hepatocellular Carcinoma Benefit From More Radical Surgeries? A Population-Based Analysis.

A Retrospective Study of PD-1/PD-L1 Combination Therapy Versus TKI Monotherapy in Elderly Patients with Uhcc.

Safety and Effectiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Aged Greater versus Less Than 80 Years

Efficacy Observation of Liver Cancer at the Later Stage for the Elderly Treated with Integration of Norcantharidin and Chinese Medicine

Transcatheter Arterial Chemoembolization Combined with Low-Dose Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma in Elderly Patients: Efficacy and Safety.

Multicenter analysis of long-term oncologic outcomes of hepatectomy for elderly patients with hepatocellular carcinoma

Herbal Medication 960 Mixture Combined with Transcatheter Arterial Chemoembolization for Advanced Liver Cancer

Clinicopathologic Features and Hepatectomy in the Elderly Patients with Primary Liver Cancer

Efficacy of Platinum Drugs in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer and Their Effects on Prognosis and Survival.

Primary liver cancer in the elderly: report of 125 cases.

Clinical Effect and Analysis of Prognostic Factors of the Elder Patients with Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization

Hepatocellular Carcinoma in Elderly: Clinical Characteristics, Treatments and Outcomes Compared with Younger Adults.

Overall Survival Rates Become Similar Between Percutaneous Ablation and Hepatic Resection with Increasing Age among Elderly Patients with Early Hepatocellular Carcinoma.